ProCE Banner Activity

Testing for EGFR Exon 20 Insertion Mutations, a New Targetable Biomarker in Advanced NSCLC

Clinical Thought
Get up to date on how and when to test for EGFR exon 20 insertion mutations in your patients with advanced NSCLC.

Released: August 05, 2021

Expiration: August 04, 2022

No longer available for credit.

Share

Faculty

Professor Keith M. Kerr

Professor Keith M. Kerr, FRCPath

Professor of Pulmonary Pathology
Faculty of Medicine & Dentistry
Aberdeen University
Consultant Pathology
NHS Grampian
Aberdeen, United Kingdom

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen Pharmaceutica NV

Faculty Disclosure

Primary Author

Professor Keith M. Kerr, FRCPath

Professor of Pulmonary Pathology
Faculty of Medicine & Dentistry
Aberdeen University
Consultant Pathology
NHS Grampian
Aberdeen, United Kingdom

Professor Keith M. Kerr, MB ChB, FRCPath, FRCPE, has disclosed that he has received consulting fees and/or fees for non-CME/CE services from AbbVie, ArcherDX, AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Debiopharm, Diaceutics, Eli Lilly, Merck Serono, Merck Sharpe & Dohme, Novartis, Pfizer, Regeneron, Roche, and Ventana.